Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

REGENERON AXOKINE AND BDNF THERAPIES ARE FOCUS OF NEW R&D STRATEGY

Executive Summary

REGENERON AXOKINE AND BDNF THERAPIES ARE FOCUS OF NEW R&D STRATEGY in the wake of the company's decision June 23 to discontinue Phase III clinical trials of its ciliary neurotrophic factor for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). As part of its "revised strategic direction" Regeneron will also concentrate on neurotrophin-3 (NT- 3), combinations of neurotrophic factors and a ligand discovery program.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024686

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel